The year 2020 also marked many remarkable achievements of the pharmaceutical company
At the National Health Digital Transformation Congress 2020, Novartis Vietnam (Novartis) was honored as one of 34 units that have made a positive contribution to the digital transformation of the health sector in the country.
Thanks to a long-term strategic vision, Novartis has been early aware of the significance of digital transformation in healthcare.
The year 2020 also marked many remarkable achievements of the pharmaceutical company.
Particularly, Novartis has pioneered the application of the Docquity platform to organizing activities and programs to provide updated knowledge for Vietnamese medical staff.
It is known that Docquity is an online community dedicated to health workers in Asia.
Moreover, Novartis has successfully partnered with health organizations and Hello Doctors to support public health awareness while cooperating with Samsung SDS in applying Brightics RA artificial intelligence technology to routine eye disease screening.
Notably, Novartis has partnered and sponsored healthcare organizations to successfully implement the program of Tam Diem.
This is a series of webinars held weekly to provide the latest scientific information for cardiologists.
Moreover, at the end of 2020, Novartis also officially launched MedHub – an online medical portal for health staff which is considered a significant milestone in the company’s digital road map to improve customer experience.
|
|
| Novartis, a pharmaceutical company, was honored in the digital transformation of the health sector. |
“We are very delighted and highly appreciate the recognition from the Vietnamese government, the Ministry of Health, and other authorities for Novartis’ continuous contributions toward the digitalization journey of Vietnam’s healthcare,” said Amitabh Dube, country president at Novartis Vietnam.
“We look forward to building the long-term, sustainable partnership and going hand in hand with Vietnam’s government in helping patients get more convenient, faster, and quality access to healthcare services.”
In early 2020, Novartis Vietnam Ltd. successfully transformed into a foreign-invested enterprise and fully operationalized its import activities.
Through long-term commitments, Novartis is supporting Vietnam’s domestic healthcare system and contributing to the country’s socio-economic development.
Novartis is a leader in innovative medicines across many therapeutic areas, namely oncology, cardiology (hypertension, heart failure, diabetes), respiratory diseases (asthma, COPD), ophthalmology, pain relief, neuroscience, dermatology and immunology, cell and gene therapy, and others.
The company is a leader in high-quality generics and biosimilars through the firm’s Sandoz arm, and one of the largest investors in clinical trials in Vietnam.
